

The 36th Sapporo International Cancer Symposium
Theme: "Advanced in Tumor Immunology and Immunotherapy"
Date: June 22–24, 2017
Venue: Royton Sapporo, Sapporo, Japan

Chairpersons:

Toshihiko Torigoe (Sapporo Medical University, Japan)
Tsukasa Seya (Hokkaido University, Japan)
Yutaka Kawakami (Keio University, Japan)

Program

Welcome Address

Hiroshi Kobayashi (Sapporo Cancer Seminar Foundation)

OPENING LECTURE

Chairman: Toshihiko Torigoe (Sapporo Medical University, Japan)
Overview: Recent advances of tumor immunology and immunotherapy
Yutaka Kawakami (Keio University, Japan)

Session 1 Tumor antigens and vaccine adjuvants

Chairmen: Cornelis Melief (Nijmegen University, The Netherlands)
Yasuharu Nishimura (Kumamoto University, Japan)

Landscape of HLA class I ligand peptides

Takayuki Kanaseki (Sapporo Medical University, Japan)

An Immunogram for the Cancer–Immunity Cycle

Kazuhiro Kakimi (The University of Tokyo Hospital, Japan)

Immunotherapeutic Responses to Cancer Neoantigens

Matthew M. Gubin (Washington University, USA)

Noninflammatory adjuvant that improves dendritic cell priming and anti–PD–L1 efficiency

Tsukasa Seya (Hokkaido University, Japan)

Nucleic acid–based vaccine and adjuvant delivered by extracellular nano–micro–particle

Ken J Ishii (Osaka University, Japan)

KEYNOTE LECTURE 1

Chairman: Yutaka Kawakami (Keio University, Japan)
Immunotherapy strategies to enhance T cell infiltration into solid tumors
Esteban Celis (Georgia Cancer Center, Augusta University, USA)

Session 2 Tumor microenvironment

Chairmen: Esteban Celis (Georgia Cancer Center, Augusta University, USA)
Hiroaki Ikeda (Nagasaki University, Japan)

Analysis of the tumor microenvironment by single cell transcriptome
Shinichi Hashimoto (Kanazawa University, Japan)

Regulatory myeloid cells in cancer. New therapeutic opportunities
Dmitry I. Gabrilovich (The Wistar Institute, USA)

A novel role of IL-34 in tumor microenvironment
Ken-ichiro Seino (Hokkaido University, Japan)

Targeting Tregs in tumors
Dario Vignali (University of Pittsburgh, USA)

Session 3 Immune surveillance and Immune checkpoint (cosponsored by Ono Pharmaceutical Co., Ltd.)

Chairmen: Naoto Hirano (University of Toronto, Canada)
Heiichiro Udono (Okayama University, Japan)

Natural and therapy-induced anticancer immunosurveillance
Guido Kroemer (French National Institute of Health and Medical Research, France)

Strategic development of combination cancer immunotherapy
Kouji Matsushima (The University of Tokyo)

Mitochondrial manipulation improves PD-1 blockade immunotherapy
Kenji Chamoto (Kyoto University, Japan)

KEYNOTE LECTURE 2

Chairman: Koji Tamada (Yamaguchi University, Japan)
Engineering T cells to effectively target and eradicate tumors
Philip D. Greenberg (University of Washington, USA)

Session 4 Combination immunotherapy (cosponsored by AstraZeneca)

Chairmen: Kazuhiro Kakimi (The University of Tokyo Hospital, Japan)
Yuji Heike (St. Luke's International University, Japan)

Immunosuppressive networks, PD-L1 Expression and Blueprint Project
Weiping Zou (University of Michigan, USA)

Complexity of immune suppressive microenvironment in cancers
Hiroyoshi Nishikawa (National Cancer Center, Japan / Nagoya University, Japan)

Strategy of Combination Immunotherapy and Immune-related Adverse Event

Shigehisa Kitano (National Cancer Center Hospital, Japan)

Session 5 Antigen-specific immunotherapy (cosponsored by Sumitomo Dainippon Pharma Co., Ltd.)

Chairmen: Ken-ichiro Seino (Hokkaido University, Japan)

Hiroya Kobayashi (Asahikawa Medical University, Japan)

Immunotherapeutic strategy targeting cancer-stem cells

Yoshihiko Hirohashi (Sapporo Medical University, Japan)

A possible Th1 cell-activating combination cancer immunotherapy using active immunization and IL-6 signaling blockade

Yasuharu Nishimura (Kumamoto University, Japan)

Strong T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer are associated with prolonged survival

Cornelis JM Melief (Nijmegen University Medical Center, The Netherlands)

Session 6 T-cell biology, engineering, and adoptive immunotherapy

Chairmen: Philip D. Greenberg (University of Washington, USA)

Hiroyoshi Nishikawa (Nagoya University, Japan)

A novel population of stem-like memory T-cells

Tomohide Tsukahara (Sapporo Medical University, Japan)

Metabolic Status of Immune Cells links with anti-Tumor Immunity

Heiichiro Udono (Okayama University, Japan)

Genetic and epigenetic modifications of antitumor T cell grafts for optimal adoptive T cell therapy

Naoto Hirano (University of Toronto, Canada)

Novel technologies in gene-modified T cell therapy

Koji Tamada (Yamaguchi University, Japan)

Extended applications of cancer immunotherapy with engineered T cells

Hiroaki Ikeda (Nagasaki University, Japan)

Closing Remarks

Yutaka Kawakami (Keio University, Japan)

Tsukasa Seya (Hokkaido University, Japan)

Toshihiko Torigoe (Sapporo Medical University, Japan)